Levosimendan in acute and advanced heart failure: an appraisal of the clinical database and evaluation of its therapeutic applications

Johann Altenberger, Finn Gustafsson, Veli Pekka Harjola, Kristjan Karason, Detlef Kindgen-Milles, Matti Kivikko, Gabriella Malfatto, Zoltan Papp, John Parissis, Piero Pollesello, Gerhard Polzl, Carsten Tschope

Research output: Contribution to journalArticlepeer-review

Abstract

The use of inotropes for correcting hemodynamic dysfunction in patients with congestive heart failure has been described over many decades. However, negative or insufficient data have been collected regarding the effects of cardiac glycosides, catecholamines, and phosphodiesterase inhibitors on quality of life and survival. More recently, the calcium sensitizer and potassium channel-opener levosimendan has been proposed as a safer inodilator than traditional agents in some heart failure settings, such as advanced heart failure. At the 2017 annual congress of the Heart Failure Association of the European Society of Cardiology (Paris, April 30-May 2), a series of tutorials delivered by lecturers from 8 European countries examined how to use levosimendan safely and effectively in acute and advanced heart failure.The proceedings of those tutorials have been collated in this review to provide an expert perspective on the optimized use of levosimendan in those settings.

Original languageEnglish
Pages (from-to)129-136
Number of pages8
JournalJournal of Cardiovascular Pharmacology
Volume71
Issue number3
DOIs
Publication statusPublished - Mar 1 2018

Keywords

  • Acute heart failure
  • Advanced heart failure
  • Inodilators
  • Inotropes
  • Levosimendan

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Levosimendan in acute and advanced heart failure: an appraisal of the clinical database and evaluation of its therapeutic applications'. Together they form a unique fingerprint.

Cite this